DocMorris stock analysis
DocMorris (0RRB) Share Price & Analysis
0RRB Stock Chart & Stats
- Day’s Range
- CHF 18.48 - CHF 19.15
- 52-Week Range
- CHF 3.92 - CHF 19.16
- Previous Close
- CHF 18.42
- Volume
- N/A
- Average Volume (3M)
- 47.17K
- Market Cap
- CHF 938.95M
- Enterprise Value
- CHF 604.15M
- Total Cash (Recent Filing)
- CHF 89.80M
- Total Debt (Recent Filing)
- CHF 265.68M
- Price to Earnings (P/E)
- ―
- Beta
- 1.26
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- -0.58
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Prescription Growth
Rapid prescription growth and materially stronger retention in electronic-prescription cohorts indicate improving customer economics and digital adoption. This can support recurring demand, higher lifetime value, and a more defensible position in the German-speaking online pharmacy market over the next several quarters.
Digital Services Expansion
Fast growth in Digital Services and TeleClinic broadens DocMorris beyond product distribution into healthcare platforms. Rising treatment volumes and doubled TeleClinic EBITDA suggest scalable, higher-margin activities that can improve the business mix and reinforce customer cross-selling.
Efficiency And Breakeven Path
The AI-First program provides a defined route to structural cost reduction, while recent margin improvement shows operating leverage is already emerging. Recurring savings and lower capital needs could strengthen profitability and support management's stated 2026 EBITDA and 2027 cash-flow targets.
Bears Say
Persistent Cash Burn
Sustained negative operating and free cash flow means growth is not yet self-funded and increases dependence on liquidity or external financing. If the planned profitability improvement is delayed, ongoing cash burn could constrain investment, reduce flexibility, and heighten funding risk.
Loss-making Operations
DocMorris remains loss-making despite modest revenue growth, and the deterioration in 2025 gross profit reduces confidence that scale alone will quickly produce earnings. Continued operating losses can limit internal reinvestment capacity and make the path to durable profitability execution-dependent.
Regulatory And Co-payment Pressure
Changes to German pharmacy remuneration, statutory discounts, and patient co-payments could pressure pricing, demand, or pharmacy economics. Higher out-of-pocket costs may increase customer price sensitivity, while regulatory scrutiny adds uncertainty to the durability of current commercial practices.
0RRB FAQ
What was DocMorris’s price range in the past 12 months?
What is DocMorris’s market cap?
When is DocMorris’s upcoming earnings report date?
How were DocMorris’s earnings last quarter?
Is DocMorris overvalued?
Does DocMorris pay dividends?
What is DocMorris’s EPS estimate?
How many shares outstanding does DocMorris have?
What happened to DocMorris’s price movement after its last earnings report?
Which hedge fund is a major shareholder of DocMorris?
What is the TipRanks Smart Score and how is it calculated?
Company Description
DocMorris
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
- Sector
- General
- Industry
- Medical - Distribution
- CEO
- Walter Hess
- Employees
- 1,337
- Website
- corporate.docmorris.com/en
- Address
- Walzmühlestrasse 49, Frauenfeld, TH, 8500, CH
DocMorris (0RRB) Earnings & Revenues
0RRB Earnings Call
Earnings Call SentimentPositive
The call conveyed materially positive operational momentum: strong Rx acceleration, rapid Digital Services and TeleClinic growth, meaningful marketing and cost efficiencies, and a credible AI-driven cost-savings plan that supports improved margins and an accelerated guidance. Key risks persist—adjusted EBITDA remains negative, operating cash flow is still negative albeit improved, net debt rose, and regulatory/co-payment dynamics could exert pressure into 2027. Overall, the positive commercial and operational progress and tightened guidance outweigh the remaining near-term financial and regulatory headwinds.
View all GB:0RRB earnings summaries0RRB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |
